The addition of a development candidate for patients with clotting factor inhibitors could further build Bayer's leadership position in hemophilia care where it offers the recombinant Factor VIII product, Kogenate(r) (antihemophilic factor
This growth was driven by record sales of ADVATE, Antihemophilic Factor
(Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, antibody therapy products, including GAMMAGARD LIQUID(TM) [Immune Globulin Intravenous (Human)] (IVIG) 10% Solution for the treatment of primary immunodeficiencies, specialty plasma therapeutics and biosurgery products.
[USPRwire, Mon Nov 19 2018] Primary factors driving Cryoprecipitated Antihemophilic Factor
Market include growing need for safe and effective guiding technology during diagnosis and prognosis procedures and safety of the medicine compared to other alternatives.
Tenders are invited for Inj Antihemophilic Factor
Viii 250 Iu
Bayer HealthCare, LLC., has announced that Kogenate(R) FS (Antihemophilic Factor
(Recombinant), Formulated with Sucrose), its recombinant factor VIII hemophilia A treatment, is now available with BIO-SET(R) needleless reconstitution system in the United States.
Sales growth in this business was driven by a 15 percent increase in the recombinant business, including $162 million of sales of ADVATE, Antihemophilic Factor
(Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A.